Emerson files for secondary listing on the Hong Kong Stock Exchange again: Revenue to double by 2025, core products already approved by the National Medical Products Administration

Ruicai Finance Wu Wenting On April 7, Wuhan Aimesen Life Technology Co., Ltd. (hereinafter referred to as “Aimesen”) submitted its prospectus to the Hong Kong Stock Exchange. The joint sponsors are Jianyin International and JiaoZiya International.

This is Aimesen’s second attempt to go public in Hong Kong. It had previously submitted its listing application for the first time on September 28, 2025.

Established in January 2015, Aimesen is an early-stage cancer detection company, with a strategic focus on cancers with high incidence rates and high mortality rates. The company was the first to develop methylation-based early cancer detection technology.

According to the prospectus, in 2024-2025, Aimesen’s revenue was 723.8 million yuan and 1541.9 million yuan, respectively; the total annual loss attributable to owners and the total comprehensive loss were 3863 million yuan and 4897.9 million yuan, respectively. It can be seen that in 2025, its revenue increased by 113.03% year-over-year.

As of the last practicable date, the company has two core products: AiXinGan for liver cancer and AiGuangLe for urothelial carcinoma, as well as four research-and-development candidate products.

Among them, AiXinGan is an internally developed non-invasive blood test product for early detection of liver cancer. It is the world’s first early liver cancer diagnostic product based on qPCR technology. The test processes plasma samples using an internally developed proprietary cell-free DNA(cfDNA) extraction and conversion reagent kit, enabling sensitive detection of trace circulating tumor DNA(ctDNA) in cfDNA. The company obtained medical device registration approval from the National Medical Products Administration in January 2025, and obtained CE-IVD certification in March 2022.

Meanwhile, AiGuangLe is an internally developed non-invasive urine test product for early detection of urothelial carcinoma. It was the first to use a novel methylation biomarker to accurately identify urothelial carcinoma, with both diagnostic and monitoring functions. The company received approval from the National Medical Products Administration in October 2025 to register AiGuangLe as a Class III medical device, and is currently developing an indication for recurrence monitoring of urothelial carcinoma and has also obtained CE certification.